NEW YORK, Dec 4 – Zyomyx and Cambridge Antibody Technology have entered into an agreement to jointly develop high-density protein chips, Zyomyx announced Monday.
Zyomyx will develop, manufacture and market the chips using its proprietary surface chemistry methods and Cambridge Antibody Technology’s library of antibodies.
“We have the core technology that enables us to immobilize proteins on surfaces and maintain their structure and function," said Zyomyx COO Lawrence Cohen. " This affords us the ability to develop miniature protein assays and still maintain the sensitivity of detection.”
Zyomyx chose CAT as a partner in order to gain access to its library of antibody fragments, which it plans to put on chips to develop arrays for large numbers of antibodies, Cohen said. Additionally, CAT has knowledge about high-throughput antibody detection that Zyomyx can use in setting up the chip reading systems.
Each company will fund its part of the research and development, although the specific details of the agreement have not been solidified.
Zyomyx also announced Monday it had raised $32.6 million in a round of series D financing, and intends to use the money to develop protein chips
Zyomyx plans to launch beta testing of these protein chips in the first half of 2001. “We are looking for additional collaborators to serve as technology access partners to help us refine the chips,” Cohen said.